What if there were a straightforward and relatively inexpensive way to lower the incidence of heart failure (HF), renal disease, stroke, and cognitive impairment? Cardiologist Bertram Pitt, MD, said ...

Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease ...

Health system pharmacists and clinicians are monitoring a wave of drug approvals expected throughout 2026, including first-in-class therapies and expanded uses of existing drugs with implications for ...

Mineralys (MLYS) is transitioning to a pre-commercial stage, supported by robust Phase 3 data and a strengthened cash ...

AstraZeneca notes baxdrostat shows reduction in systolic blood pressure in phase III of uncontrolled or resistant hypertension: Our Bureau, Bengaluru Monday, January 5, 2026, 18:0 ...

Detailed price information for Cspc Pharmaceuticals Group Ltd (CHJTF) from The Globe and Mail including charting and trades.

An announcement from Mineralys Therapeutics, Inc. ( ($MLYS) ) is now available. On January 6, 2026, Mineralys Therapeutics provided a corporate ...

Formal written minutes from the U.S. FDA confirms no major concerns identified for the planned Phase 3 PANDA study of ...

The authors conclude that lorundrostat shows promise as an effective blood pressure–lowering therapy for patients with ...

Boehringer Ingelheim has unveiled its second kidney-focused collaboration in recent weeks, this time penning a ...

The full data from AstraZeneca's phase 3 BaxHTN trial of baxdrostat has raised hope of an important new treatment option for people who struggle to control their blood pressure with current therapies.

Formal written minutes from the U.S. FDA confirms no major concerns identified for the planned Phase 3 PANDA study of [68Ga]Ga-PentixaFor in treatment-resistant hypertension and Primary AldosteronismT ...